OKYO Pharma Boosts Cash to Advance Phase 3 Urcosimod Trial
London, United Kingdom, and New York, NY | July 20, 2026 OKYO Pharma Limited announced the filing of its...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
London, United Kingdom, and New York, NY | July 20, 2026 OKYO Pharma Limited announced the filing of its...
LONDON and NEW YORK, July 8, 2026 OKYO Pharma announced positive feedback from its U.S. Food and Drug Administration...
